EL.En. S.p.A. (ELN) Earnings Call Transcript & Summary

May 16, 2023

Borsa Italiana IT Health Care Health Care Equipment and Supplies earnings 49 min

Earnings Call Speaker Segments

Bianca Mastelloni

executive
#1

Good afternoon, or good morning, everyone, and welcome to the conference call on El.En's financial results for the first quarter of 2023. This call is being recorded today, and there will be a chance to ask questions at the end of it. Joining me are Andrea Cangioli, El.En's CEO, and Enrico Romagnoli, El.En's Chief Financial Officer and Investor Relations. Before we start, please be aware that management will make remarks on this conference call regarding future expectations, plans and prospects, which are forward-looking statements. Some statements on this call, including those dealing with the company's beliefs, plans, objectives, beliefs or expectations of possible future results or events, are forward-looking statements. Forward-looking statements carry known or unknown risks, including general economic and business conditions and conditions in the industry in which we operate, and may be affected if our assumptions prove inaccurate. As a result, no forward-looking statement can be guaranteed, and other future results, performance or achievements may differ materially from those expressed or implied by such forward-looking statements. The company assumes no obligation regarding the content, or to update the forward-looking statements, to reflect events or circumstances that may arise after the date hereof. If you would like to ask a question, please book your question at the top of Barbara Poli.

Bianca Mastelloni

executive
#2

She'll be glad to introduce you once the booking order comes through. Right now, I'd like to hand things over to Andrea Cangioli. Andrea, please go ahead.

Andrea Cangioli

executive
#3

Thanks, Bianca, and thanks to everyone for joining us following the first-quarter 2023 financial results. I'm here with Enrico Romagnoli, and you can see the two of us on the same screen today. Our consolidated results for Q1 2023 came in perfectly in line with the guidance we gave for the full year 2023. Revenue grew a bit above 10%. EBIT was roughly unchanged from the first quarter of 2022. That's the external envelope of the results. Going a level deeper, business dynamics varied considerably by market segment, and in some cases they differed somewhat from the trends we expected for the full year. Let's begin with commentary on trends in the medical business. Growth came in above 11%, an excellent outcome on top of a record year, which 2022 was. Gross margin rose versus Q1 2022, and although staff expenses and sales and marketing expenses did increase, the EBIT margin was essentially in line with Q1 2022. We saw good sales traction in skin treatments, both in the ablative area with CO2 and laser systems for rejuvenation, and in ultrashort pulse pico- and nanosecond laser systems for tattoo removal and skin toning.

Andrea Cangioli

executive
#4

In hair removal, both sales and order bookings came in weaker, a segment that had seen remarkable growth during 2022. As I mentioned earlier, several factors drove the improvement in margin on sales during 2023. First, the reduced proportion of high volume hair removal devices, which carry a thinner sales margin. Second, higher sales volume in some of the higher margin systems. Third, the modest price increase, which helps counterbalance the substantial rise in cost of goods that we are absorbing. Fourth, foreign exchange dynamics, particularly involving the US dollar, which is weaker today than at the close of 2022, yet remains stronger than it was in the first quarter of 2022. On the expense side, sales and marketing costs went up. Business travel and trade fairs have returned to pre-COVID levels, and activity was fairly intensive during the quarter, with a number of annual events landing at the end of March. Turning to the coming quarters, expense will remain above the 2022 level because more events are on the way, such as the World Congress of Dermatology, which is held every fourth year. The previous edition took place in Milan, Italy in 2019, and the 2023 edition will be hosted in Singapore, a very costly venue. These expensive sales and marketing activities are necessary at this stage, when demand remains quite satisfactory but is no longer as buoyant as it was one year ago.

Andrea Cangioli

executive
#5

In recent months, orders and deliveries have come in at solid levels. However, rising interest rates and doubts about how strong the global economy will be are pointing toward slower growth in sales volume next month. For Cutlite Penta in the laser cutting business across Western markets, business results were outstanding, with sales volume climbing sharply in Q1 2022, reflecting the progressive effect of the continuous growth achieved in 2022. Profitability was also satisfying, helped by a more favorable sales mix, since demand and sales proved stronger than the best in the higher margin export business. That trend ought to consolidate across the year, reflecting the intense preparatory work done in creating or consolidating the export distribution networks, and also because of relatively softer demand expected in Italy, where the tax cut granted under the so-called Industry 4.0 provisions are reduced in 2023. The other smaller businesses within the industrial sector did quite well in the quarter. I'm referring to the marking business with Lasit and Oplas, and the laser sources business managed by LM. Financial results in these segments met expectations in terms of profitability, and were slightly better in terms of sales volume.

Andrea Cangioli

executive
#6

The segment that fell short during the quarter was the Chinese portion of laser cutting, where following a sluggish fourth quarter of 2022, we posted a quarter at the start of 2023 that was slower still. The prolonged lockdown measures dealt a severe blow to China's economy and to demand in this application market. Order booking and demand were quite weak, and competition in the market kept intensifying all through 2022. Once the lockdown policy finally ended in late December, after a long wait, both the Chinese economy and our markets have been recovering, and the outlook today looks better than what the results of the past six months suggested. Q1 began without a solid order book behind it and only gained genuine momentum after the Chinese New Year holiday concluded in the middle of February. Order intake has been satisfactory, and the next quarter should show the payoff. Margin pressure from tougher competition has been building in the market that declined steadily through 2022, and it shows clearly when comparing sale margins from early 2022 against those of early 2023.

Andrea Cangioli

executive
#7

For 2023, our guidance in the cutting business depends on a robust recovery in China — something that did not happen at all during Q1, though we are counting on it over the quarters ahead. As we shared in our reports and in our meetings, the laser cutting division is carrying out work meant to get ready for an IPO filing on a financial market in Mainland China. Meeting CSRC requirements — the Chinese Commission, or SEC — is no easy job for an issuer with a substantial international footprint and a foreign controller. That slowed our preparation down. What right now keeps us from starting the formal filing process isn't compliance — it's how solid the financial results are, since they need to be stronger to support a successful transaction. One more topic that warrants a few remarks, beyond the report Enrico will give you in a few minutes on how the group's net cash position changed, is the trend in net working capital. Naturally, its effect on the net financial position. At the close of March, consolidated net working capital rose by roughly EUR 25 million during the quarter, reaching EUR 125 million in total — equal to 32% of revenue for the last 12 months, up from 30% at the end of December 2022 and 25% as of December 2021.

Andrea Cangioli

executive
#8

During the fourth quarter, we were able to bring net working capital down. Over the course of the year, we intend to keep its level in check. The trend in this first quarter showed considerable expansion, since those figures remain above the growth in revenue. Because we had to buy ahead to keep delivery delays from putting our production schedules and pace at risk, the production cycle across our activities lengthened. That impact from strains and problems in the supply chain persists. We do not have confidence yet in stepping back from costly purchasing. Our buying plans rest on a yearly forecast and would tend to carry more weight in the opening quarters of the year, so that our manufacturing can still hit its targets — which, unless sales volume materially exceeds the planned, the planned volumes, results in higher inventory, and that is the largest contributor to the rise in working capital. Days of sales outstanding in receivables in fact got better during the quarter, while we also kept improving payment terms for our vendors — improving them for the vendors, I mean — which is part of the burden falling on us as we try to prevent supply chain problems. Still, I think the 11% and change revenue increase is an excellent result for the period, as I will elaborate shortly, our growth plans for 2023 were more ambitious at the end of 2022 than they are today.

Andrea Cangioli

executive
#9

So actual sales came in below what we had projected, and that also had an impact on our finished goods inventory. That's not something we're worried about — it will get absorbed and handled over the coming months or quarters. One more item that affects our cash position is how customer deposits and vendor deposits are trending. Normally, the customer deposits balance goes up when the order book grows, and it goes down when the order book shrinks. During the quarter, that balance fell by close to EUR 4 million, largely because of a decline in one particular part of the order book — the segment tied to the 4.0 tax cut, which called for an advance payment before the end of last year so that the beneficiary could take advantage of the cut. Vendor deposits went up by about EUR 4 million during the quarter, which is another way we protect ourselves so that supplies arrive on time, as we talked about earlier. I'll come back with comments on the general trend once Enrico walks you through the detailed financial reporting.

Enrico Romagnoli

executive
#10

Thanks, Andrea. As Andrea already noted, sales were up 12% in Q1 2023. Over that same period, gross margin rose to EUR 61.1 million, an 11% gain, roughly matching the sales growth. The impact on sales showed a small decline, from 38.1% in the first quarter of 2022 to 37.9% in Q1 2023. Sales margin improved slightly in the medical sector, where the product mix sold was more favorable, and price increases helped offset higher material costs. In the industrial sector, by contrast, margin on sales fell, mainly because of difficulties in the China market. On operating expenses, both the total value and the impact on sales went up, with that impact rising from 8.2% to 8.7%. The chief cause is system marketing costs for trade shows and congresses, driven by both medical and industrial customers. Staff costs are rising too, with a slight increase in their impact on sales as well. As of March 31st, the group had over 2,200 employees. Most of the increase, 90 units, comes from personnel at the newly acquired KDS in Switzerland, while the remaining new hires mainly concern Atec in Germany, a company with a growth rate of 15% in the quarter, and Quanta System, with a growth rate of 21% in the quarter.

Enrico Romagnoli

executive
#11

For EBITDA, it came to EUR 21 million, which represents a 4.3% rise versus the EUR 20.1 million recorded in Q1 of the prior year. Our EBITDA margin stood at 15%, a modest decline compared with last year's first-quarter EBITDA, which was 13.9%. Depreciation and other accruals went up because of investments made in the past and a higher bad debt reserve, although the effect on sales overall is more or less steady. EBIT came in positive at EUR 17 million for the quarter, a slight decrease from the EUR 17.1 million posted in March 2022. The EBIT margin of 10.6% is likewise a bit lower than the 11.8% seen in 2022. Pre-tax income, hit by negative Forex, was positive at roughly EUR 16.6 million, a 5.3% drop from the EUR 17.5 million of Q1 2022. At quarter-end, the group's net commercial position was positive by approximately EUR 56.7 million, versus EUR 88.5 million at the close of last year — a reduction of around EUR 32 million. On cash flow, the expansion of net working capital needed to safeguard production-process stability, also with a view to a further rise in volumes produced, absorbs roughly EUR 36 million in cash, plus more than EUR 60 million stemming from changes in our payable and receivable, including more advanced payments to suppliers, fewer advanced receipts from customers, and a higher VAT credit.

Enrico Romagnoli

executive
#12

You should also note that fixed asset investment during the period came in above EUR 4 million. As a reminder, on May 31st the group pays a dividend of EUR 0.22, amounting to a total payout of EUR 17.5 million. The medical sector, looking at... The medical sector posted growth above 11%, driven by positive contributions from every segment. Revenues and quarterly order acquisition confirm the market is in excellent health across all applications: aesthetics, surgery and therapy. Consistent with the forecast for the full year 2022, growth proved more pronounced in the surgical sector, though aesthetic application also delivered an interesting result. The main medical segment, with a 57% share of medical sales, close to 10%, and in the therapy sector. In the industrial sector, revenue growth was close to 13%. The laser cutting segment accounts for roughly 80% of the sector, a share achieved through constant and rapid growth in recent years and expected in the current year as well. In Italy, Cutlite Penta delivered an excellent result with 70% growth, which offset the decline in turnover of the China business. Revenue growth in laser marking was very interesting, exceeding 62%, thanks to the excellent performance of both Lasit in marking for identification and Ot-Las for decoration and special process.

Enrico Romagnoli

executive
#13

Medical sector sales are trending favorably across every region, with the strongest numbers coming from business outside Europe. Turning to industrial sector sales, I'd point to the very fast revenue growth in Italy and in Europe, while the Chinese market pulled back, which produces a 26% decline in non-European sales. Andrea, over to you.

Andrea Cangioli

executive
#14

All right. As I said earlier, our expectations for 2023 were higher than where we stand today at the close of 2022. We remain confident today in our capacity to turn in another very strong performance this year, but our projections have to be more cautious so as to factor in a global economic climate that is currently turning out colder than anticipated. The drivers behind the growth we expect for our main businesses are firmly in place, resting both on overall consumption trends in the medical aesthetic segment and in the surgical segment, and on our capacity to bring to market innovative technological solutions that meet market needs, and that also add to anticipated market growth by introducing new applications, in the medical as well as in the industrial sector, which widen the market potential. The overall economic trajectory affects our market trends and our results, an effect we take pride in being able to minimize thanks to the appeal and the ongoing innovation of our product range, yet it does have an impact all the same. What we sell is capital goods, and we rely on our customers' confidence when it comes to committing to investments that can be rather significant for their pockets.

Andrea Cangioli

executive
#15

Both inflation and interest rate increases directly affect customers who are facing a pricier purchase and will also carry higher monthly lease installments. That, combined with the generally downbeat economic expectation news of recent months—particularly in the United States—is producing an overall climate that makes approaching our markets more complicated than it was in 2022, when, aside from China and the broad effect of the Ukrainian war, things were, by the way, absorbed rather well. The outlook had appeared bright, with strong confidence regarding future economic developments. Having said all that, we reaffirm the 2023 guidance delivered last March. Revenues are set to grow in 2023, in both the medical and the industrial sector. Owing to several factors, ranging from lower gross margins to higher sales and marketing expense to the overall rise in operating expenses that will lower operating leverage within the expected revenue range, the 2023 EBITDA target is to match the 2022 results. That concludes our prepared remarks. We are now ready to take your questions.

Bianca Mastelloni

executive
#16

Andrea, we don’t—there’s nothing in the queue. We could check whether any investor has a question for you.

Andrea Cangioli

executive
#17

That was a very thorough report, and I don’t think there’s anything else to ask. All right.

Analyst

analyst
#18

Testing the mic. Can you hear me?

Andrea Cangioli

executive
#19

Yes.

Bianca Mastelloni

executive
#20

Yes.

Analyst

analyst
#21

Hello, apologies. No, I didn’t notice who had booked the question for the Q&A. Sorry about that. Thanks for taking my questions. My first one concerns what we expect from the Chinese business. If you could comment on how trading is right now. And if you could return to what you said regarding the project for an IPO in the region, since I missed part of your remarks. That’s my first question. Thank you.

Andrea Cangioli

executive
#22

All right. In China, business was extremely sluggish during the first quarter. Sales volume was definitely below Q1 2022 and definitely below what we had expected. Still, the reasons behind this underperformance need to be examined in the weak results of last year and the poor order books inherited from 2022 to 2023. The Chinese situation began to improve once lockdown policies were lifted at the end of 2022. Traveling and life returned to normal, both in day-to-day life and in business life. The first three months of the year are usually affected by the New Year's break, which took place in the first days of February this year. We started working again and looking for POs for our production, really starting from February. I mean, current trading is positive. There is a good order inbox in this 1st month, which is promising for the 2nd quarter and for the following quarters. After one year of deep downturn, though, the situation turned, and it is today more competitive than it was at the beginning of 2022. This is quite evident in the reduced margins on sales that we have to accept in order to increase the sales volume.

Andrea Cangioli

executive
#23

We're working to improve, as always, by positioning our product range at a higher standard than the market average. Right now we're up against a very competitive market. Regarding the IPO, I gave a detailed comment. On one hand, I said we've been working to make our businesses compliant for an IPO on mainland China, which is quite complex because almost 50% of the business is operated outside of China, and we have a foreign controller for a Chinese company seeking a listing on a mainland China market, which is not ordinary at all. Beyond the compliance issues, the weak results of Q1 2023 suggest that we see how the business is developing, and we'll wait for sounder financial results before we approach the listing with a formal IPO application.

Analyst

analyst
#24

Thanks once more, Paolo Salvadeo. On the second question, I’ll leave the floor for other questions, but that second question concerns the component — the EUR 16 one-sixth million component of cash absorption tied to more favorable payment terms that you extended to clients and suppliers. What I mean is, could you give us a sense of which segments are receiving these kinds of favorable conditions? Is it the aesthetical segment, for example, or particular areas? Just so we understand where you’re granting these more favorable conditions. Thank you.

Andrea Cangioli

executive
#25

So actually, I think that EUR 60 million isn't entirely composed of advances to suppliers. That EUR 60 million really breaks down into three pieces. The cash absorption is EUR 60 million. EUR 4 million of it comes from a reduction in down payments from customers, mostly in industrial and mostly in Italy. That's a consequence of the Industry 4.0 effect, since everyone made down payments at the end of last year so they could capture the Industry 4.0 tax cut in 2022, and now we're delivering against those deals. EUR 4 million is advances to vendors, and that's fairly widespread. I'd say it's mostly supporting the medical business. It's mainly there to support the medical business, with only marginal support for the industrial business. When it comes to purchases, medical, aesthetic and medical surgery actually share one purchasing system. There isn't a separate system, because they operate in the same manufacturing facilities. No differentiated purchasing procedure exists for surgical versus aesthetic. There's just one purchasing function for medical. The remaining EUR 8 million comes from the change in tax debit and tax credits, and the increase is mainly tied to higher VAT credits during the period.

Analyst

analyst
#26

Thanks once more. My apologies for raising a point you’d already addressed — I hadn’t caught the reconciliation you’ve just given me.

Andrea Cangioli

executive
#27

No, no — Andrea, I put in additional details. What you asked helped.

Analyst

analyst
#28

All right. Thanks, and I’m looking forward to seeing you in Florence.

Andrea Cangioli

executive
#29

Oh, of course. Of course. Yes.

Bianca Mastelloni

executive
#30

Next up, we have a question from Carlo Maritano at Intermonte. Please go ahead, Carlo. Carlo?

Andrea Cangioli

executive
#31

We’re unable to hear him.

Bianca Mastelloni

executive
#32

Carlo Maritano? You’ll need to unmute yourself, perhaps.

Andrea Cangioli

executive
#33

I think—

Bianca Mastelloni

executive
#34

That's perfect. Carlo?

Carlo Maritano

analyst
#35

Is this coming through clearly now?

Andrea Cangioli

executive
#36

Correct.

Bianca Mastelloni

executive
#37

Correct.

Carlo Maritano

analyst
#38

All right, thank you for taking my question. I wanted to ask about net-net working capital. You partly addressed this in your answer to Andrea, but I'm curious what we should expect for the rest of the year. If demand turns out somewhat softer than it was in the first quarter, should we anticipate some cash generation from net working capital, or given that the supply situation is still uncertain, will you stay cautious, particularly when it comes to inventory? Thank you.

Andrea Cangioli

executive
#39

Usually, the more we, shall we say, ensure that balances align at year-end. Right now we're still, I mean, examining our one-year plan. We continue to operate with production rates established to achieve specific output volumes required to satisfy specific sales volumes. As I noted in my remarks, sales volume during Q1 came in somewhat below what was initially anticipated when the year began. Well, we've adjusted production volume and, to some degree, we also adjusted purchasing for the second quarter, and it's premature to tell because we're halfway through the second quarter. Whether we can actually deliver goods across these 6 weeks of the second quarter will settle whether we'll manage to bring down, sharply bring down net working capital by a significant margin. My impression is — and we're working toward that reduction — that we can make Q1 2023 net working capital the peak amount for 2023. Based on what we observe today, we ought to be capable of reaching that objective. Once more, this hinges on our delivery capability, which in turn hinges on our customers' ability to meet their payment schedules on time.

Andrea Cangioli

executive
#40

Back in 2022, everything was simpler. Now in 2023, we've returned to a more normal situation, though it's still quite positive. In 2022, our sole commitment involved getting the goods ready for delivery; these days, we also have to ensure our customers are prepared to accept that delivery. That makes things a bit more complex. It remains very positive, just somewhat more complex. To address your question, we're confident that by the close of the second quarter of 2023, net working capital's effect on revenue for the last 12 months will be lower than at the end of March.

Carlo Maritano

analyst
#41

Thank you.

Bianca Mastelloni

executive
#42

Andrea, there aren’t any further questions from us. From the investor side, though, I’d simply like to ask you about some questions they have. Is there anything else?

Analyst

analyst
#43

Mind if I ask something? I’ve got one question.

Bianca Mastelloni

executive
#44

Sure, go ahead.

Analyst

analyst
#45

Yeah. Andrea, how long would the Chinese business need to be at normalized earnings before it could IPO? I mean, obviously Q1 was weak. We're going to see improvement over the rest of the year. Does that Chinese business have to be on stable footing for at least 12 months, or maybe two years, before an IPO could happen? How long do you think that normalized period would need to be for it to be able to IPO?

Andrea Cangioli

executive
#46

Right. There are two things we need to see: positive results, stable results, and a positive outlook. At this moment, in this Q1, we have negative results and a decent outlook, but not — I believe it will take a few quarters. A few quarters will be needed. I don't think we're in a position to file for an IPO reference, the June 30, 2022. That means we'll probably have to wait at least until we can file with reference to the yearly results.

Analyst

analyst
#47

Alright.

Andrea Cangioli

executive
#48

Nothing is finalized and nothing is certain at this point, since we weren't able to file using 2022's underlying numbers; we're hoping we can manage it with the full 2023 figures. At the start, we had an expectation and a hope of filing with the June 2023 numbers, but following the extremely, extremely slow Q1, we think that possibility is extremely, extremely slim.

Analyst

analyst
#49

Yeah, one more thing I wanted to ask: on the medical side in Singapore, are you going to launch something new and innovative — something exciting — or is that not going to happen?

Andrea Cangioli

executive
#50

Yes. Yes. An enhanced high-power hair removal device is coming, and it's much anticipated; it should help revitalize — I mean, reboost — a market that, after an exciting 2022, is now, let's say, not registering growth in 2023. We'll present the improved version of the Red Touch, our dermatology device that emits in the red at 675 nanometers, a great non-invasive rejuvenation device. And it's also able to treat dyschromic diseases. On this Red Touch device, I'd also like to add that not only are we introducing it in its enhanced RedTouch PRO format, but we're also launching a clinical study aimed at the release by the FDA of the clearance for sale of the device in the United States. We have not been selling the device in the United States yet because we didn't have an FDA clearance. We plan to get this clearance in the coming 12 months, so it won't be a 2023 event. It will be a 2024 event. We believe that that device could be extremely significant in the sales mix of 2024. These are the main points. We have concerning new products. We are developing a new body shaping device for the U.S.

Andrea Cangioli

executive
#51

When it comes to a market built on a new technology versus the one we currently have in place — the one we have right now — we'll be submitting for FDA clearance, and our hope is that we can already be selling it for revenue in Q4 2023, or at the latest Q1 2024.

Analyst

analyst
#52

Alright, one final question. You clearly don’t disclose this figure, but consider book-to-bill — that is, orders received compared with revenue. Put another way, whether the backlog is expanding or contracting. What are you observing right now on the industrial side and the medical side? Are you receiving as many orders as you are shipping products and recording revenues? Or what do the trends look like at present?

Andrea Cangioli

executive
#53

That's a tough one to answer. Let me give you the industrial side: our book-to-bill — well, bill, actually, at this moment book is running above bill. In Q1, for certain, bookings have exceeded billings. That's clear across the whole industrial segment. On the medical side, it's the reverse, though the situation there is different, since in many cases those orders are yearly ones. What I mean is, book-to-bill is clearly lower, and the reason is that we build up our order book at year-end and then work it down across the year, because those are blanket orders spanning 12 months. What I can say is that 2022 followed the same pattern. Orders peaked in December 2021, then declined, and we peaked the order books once more in November 2022. Today, our order books are being depleted at a quicker pace than a year ago, and that's also because capacity has gone up. This again shows up in the fact that we have less confidence in what the 2023 growth rate will actually be. We don't think we'll be in a position to match 2022's growth in 2023 — I mean, the trend itself isn't negative.

Andrea Cangioli

executive
#54

The direction remains favorable. It's weaker than what we saw last year.

Analyst

analyst
#55

Understood, thank you.

Andrea Cangioli

executive
#56

Glad to have you with us.

Bianca Mastelloni

executive
#57

I'd like to check with the floor once more to see whether anyone else has a question. Andrea?

Andrea Bonfà

analyst
#58

Good morning, this is <<inaudible>> calling from Mediobanca.

Bianca Mastelloni

executive
#59

Andrea Bonfà: Marco — Marco, you have the floor.

Andrea Cangioli

executive
#60

Marco and Andrea.

Andrea Bonfà

analyst
#61

Hi there, Andrea. Hi, Enrico. How are you both doing?

Andrea Cangioli

executive
#62

Hello.

Andrea Bonfà

analyst
#63

Good, good to talk with you once more. I’ve got a question about the component situation. You said the situation and the supply chain remain under stress. I recall that last year — or on the previous call — you said you were raising pricing and coping by substituting components. Could you say a bit more about where things stand, and are you thinking about increasing prices again, perhaps?

Andrea Cangioli

executive
#64

At the close of 2022, we implemented price hikes within our medical segment. A portion of those increases has since been reversed. Certain ones remain in place. We're dealing with cost inflation. Cost of goods sold is affected. Take a laser system that ran us 100 at the start of 2022 — by the end of that year, it ran us at least 105. We pass part of that added cost along through our pricing. Things look somewhat different on the industrial side, since we've been up against falling prices, and those falling prices persist. Instead of raising prices, we've stopped cutting them at the pace we previously did. There isn't an inflationary impact — rather, it's a slower deflationary one, in a market where prices are declining thanks to rising production productivity and lower costs for the key components. Regarding supply chain strains, as I noted in my report, they persist. That means to secure deliveries, we must make purchases several months ahead of time. To avoid being overly tight in our forecasting models relative to real production requirements, we have to buy earlier, and this essentially lengthens the manufacturing cycle while raising the cash tied up within it — typically in the inventory of materials.

Andrea Cangioli

executive
#65

From this perspective, right now, we still believe there’s a real chance to grow volume quite substantially. We’re continuing on. We aren’t scaling back what we put into inventory, since we view that as a sound investment that helps guarantee we can supply the volumes our customers request from us.

Andrea Bonfà

analyst
#66

Yeah, that's very clear. Thanks. I've got another question about your investment in Accure. One of Terra's biggest competitors in the U.S. — or maybe the biggest — appears to be in something of a turmoil. Do you think that could potentially be a benefit for your investment in Accure?

Andrea Cangioli

executive
#67

Right now, we're running a limited marketing launch program. It's aimed at an early adoption plan involving top recruited dermatologists and physicians. The goal is to set and establish what we believe is the Accure system's superior performance relative to our competitors' systems, and the excellent performance our Accure system can achieve.

Bianca Mastelloni

executive
#68

Andrea, we're done.

Andrea Cangioli

executive
#69

Go ahead. Could you expand a bit on what the industrial laser opportunity in the USA could look like? Yeah, that's an interesting potential. We don't yet have a solid presence there, but we've begun selling our high power lasers for laser cutting in U.S. territory. We'll be at FABTECH, which takes place in Chicago this year. We'll be there with a stand and with a distributor. So even though for 2023 we expect to sell a few units, it won't materially affect the business. I think we're planting the seeds, and we'll also flank that with an appropriate service package to support our installations in the United States. I believe this market could become progressively interesting as we move forward into 2024.

Bianca Mastelloni

executive
#70

Andrea, is there anything else you'd like to ask? Does anyone else in the room have a question? Alright. Since no further questions remain, we'll bring this conference to a close. Should you have any matters you'd like to look into, feel free to reach out to Enrico Romagnoli. He'll be glad to respond to whatever you need. Thanks for joining us at this conference, and we look forward to having all of you back next time. Good afternoon, everyone. Bye.

Andrea Cangioli

executive
#71

With that, I'll say see you next time. Our company visit is coming up on May 30. We'd be delighted to host you and to the visit, which also includes a stop at the Calenzano plant as well as at the Cutlite Penta plant of the laser cutting systems.

Bianca Mastelloni

executive
#72

I really appreciate it.

Andrea Cangioli

executive
#73

Thanks.

Bianca Mastelloni

executive
#74

Thanks, everyone. Bye.

Andrea Cangioli

executive
#75

Bye. Bye-bye. Bye-bye.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete EL.En. S.p.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to EL.En. S.p.A. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in EL.En. S.p.A. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.